Research grade biosimilars from Absolute Antibody are antibodies with the same sequence as their therapeutic counterparts, produced using a recombinant platform. This technology allows production of materials free of the excipients and/or additives which might be found in the therapeutic formulations. Their purity is higher than 98% (determined by SDS-PAGE), have no antibody fragments, and have endotoxin levels below 1.0 EU/mg (determined by LAL). All research grade biosimilars are supplied in PBS buffer with 0,02% Proclin 300 as preservative.
Absolute Antibody’s broad range of biosimilars includes: Trastuzumab, Muromonab, Campath-1H, Rituximab, Infliximab, Daclizumab, Basiliximab, Cetuximab, Satumomab, Acritumomab, Abaciximab, Eculizumab, Efalizumab, Clenoliximab, Ruplizumab, Matuzumab, Humicade, Volociximab and most recently added Oxelumab.